RxDoctor Payments DataLook up a doctor →

Devon Driver

Family · Columbia, SCNPI 1821432899

Payments from drug & device makers

$21,384in general payments, 2019–2025

Across 1,142 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Sun Pharmaceutical Industries Inc.$2K
  • Mayne Pharma Commercial LLC$2K
  • Johnson & Johnson$1K
  • plus $10K from 27 others

What the payments were for

  • Consulting fees$1,1405%
  • Food & beverage$19,55891%
  • Education$6863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,384 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$277,037
Medicare patients
860
Services billed
5,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab28$370,224
Dupixent PenDupilumab22$140,363
OtezlaApremilast12$63,369
Ketoconazole171$3,413
Clobetasol Propionate80$3,042
Fluorouracil32$2,493
Tacrolimus18$2,337
Doxycycline Hyclate56$2,084
Calcipotriene18$1,846
Ammonium Lactate62$1,259
Mometasone Furoate55$947
Metronidazole31$929
Azelaic Acid12$823
Triamcinolone Acetonide62$732
Clindamycin Phosphate26$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,162$63,36912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →